CSCs have been identified in breast cancer by different markers (primarily being CD44+/CD24low/−), and by their ability to generate a heterogenous cell population, resist chemotherapy and express an epithelial-to-mesenchymal (EMT) phenotype [12,13,14]. This evidence concerns the gene CD44 and breast carcinoma.